BRAF Mutation Occurs in a Majority of Papillary Thyroid Carcinoma

The BRAF gene was recently found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested a large number of primary tumors by PCR amplifications of BRAF exon 15 followed by restriction enzyme analysis and found a 68% frequency of a missense T to A transversion at nucleotide 1796 in papillary thyroid carcinoma. Our data suggest that activating BRAF mutations are an important event in the development of papillary thyroid cancer. This mutation provides a basis for novel diagnostic and therapeutic applications in thyroid cancer. Description (Set) Proposed Use (Set) Identified a common mutation in a tumor type, sets basis for extended diagnostic and therapeutic applications. Patent (Set) 7,378,233

Inventor(s): Sidransky, David

Type of Offer: Licensing



« More Diagnostic Patents

---